{"filing":{"accession_number":"0001437749-26-031281","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"eton20260923c_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926031281/eton20260923c_8k.htm"},"events":[{"id":35294,"run_id":32503,"accession_number":"0001437749-26-031281","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Eton Pharmaceuticals announced the commercial launch of IMPAVIDO® (miltefosine) capsules with exclusive U.S. commercialization rights and integrated patient support programs. This is a material operational and commercial milestone for a rare disease pharmaceutical company—the launch of a marketed product with full commercial infrastructure represents a significant business event, though it does not fit the specific categories of M\u0026A, earnings, or other defined event types. The disclosure emphasizes the company's rare disease focus and the integration of patient support services, making this a material operational event.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39304,"accession_number":"0001437749-26-031281","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Eton Pharmaceuticals announced the commercial launch of IMPAVIDO® (miltefosine) capsules with exclusive U.S. commercialization rights and integrated patient support programs. This is a material operational and commercial milestone for a rare disease pharmaceutical company—the launch of a marketed product with full commercial infrastructure represents a significant business event, though it does not fit the specific categories of M\u0026A, earnings, or other defined event types. The disclosure emphasizes the company's rare disease focus and the integration of patient support services, making this a material operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:17:40.682119+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39304,"accession_number":"0001437749-26-031281","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Eton Pharmaceuticals announced the commercial launch of IMPAVIDO® (miltefosine) capsules with exclusive U.S. commercialization rights and integrated patient support programs. This is a material operational and commercial milestone for a rare disease pharmaceutical company—the launch of a marketed product with full commercial infrastructure represents a significant business event, though it does not fit the specific categories of M\u0026A, earnings, or other defined event types. The disclosure emphasizes the company's rare disease focus and the integration of patient support services, making this a material operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:17:40.682119+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-09-28"}]}